Beyond ten cycles of cabazitaxel for castrate-resistant prostate cancer.
Loading...
Date
2014-07
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: There are limited data regarding cabazitaxel use beyond 10 cycles. Patients and Methods: Retrospective analysis of prospectively collected data of patients with metastatic castrate-resistant prostate cancer who received over 10 cycles of cabazitaxel after docetaxel failure. Results: Four patients received between 14 and 27 cycles. Reasons for stopping cabazitaxel were toxicity (2), progression (1) and logistics (1). Two of the three patients with measurable disease attained a partial remission (PR). Three patients continued to have a PSA response after 10 cycles; PSA nadir occurred between 17 and 23 cycles. Other than peripheral neuropathy (PN), all the cabazitaxel-related toxicities occurred after the initial cycles and did not increase cumulatively. Clinically significant neuropathy occurred after 15-17 cycles. The cabazitaxel-induced PN was partially reversible, with improvement from grade 3 to grade 2 after a 3-5-month long drug holiday. Conclusion: Cautiously continuing cabazitaxel until progression or intolerable toxicity may maximize efficacy.
Description
Keywords
Cabazitaxel, carcinoma, cycle number, extended, neuropathy, peripheral nerve disease, prolonged chemotherapy, prostate
Citation
Noronha V, Joshi A, Prabhash K. Beyond ten cycles of cabazitaxel for castrate-resistant prostate cancer. Indian Journal of Cancer. 2014 Jul-Sep; 51(3): 363-365.